Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	1.62B -24.0%
Revenue (ttm)	868.45M +21.5%
Net Income	158.69M +9.1%
EPS	2.71 +8.0%
Shares Out	57.60M
PE Ratio	10.40
Forward PE	8.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,006,730
Open	27.66
Previous Close	26.87
Day's Range	25.90 - 29.31
52-Week Range	25.52 - 40.87
Beta	0.84
Analysts	Strong Buy
Price Target	50.13 (+77.83%)
Earnings Date	Feb 24, 2026

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in P...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 268
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY
• Website: https://www.harmonybiosciences.com

Financial Performance

In 2025, HRMY's revenue was $868.45 million, an increase of 21.51% compared to the previous year's $714.73 million. Earnings were $158.69 million, an increase of 9.07%.

Analyst Summary

According to 8 analysts, the average rating for HRMY stock is "Strong Buy." The 12-month stock price target is $50.13, which is an increase of 77.83% from the latest price.

Price Target

$50.13

(77.83% upside)

Analyst Consensus: Strong Buy